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Abstract
An overall assessment of the pharmaceutical sector in the Republic of Moldova was 
performed during 2011–2012, with the purpose of providing the Ministry of Health 
with comprehensive evidence regarding access to essential medicines of good 
quality. This report presents the results, based on a secondary analysis of evidence 
collected during a series of assessments conducted by the World Health Organization 
Regional Offi  ce for Europe in collaboration with the Ministry of Health of the Republic 
of Moldova, the Medicines Agency, Nicolae Testemitanu Republic of Moldova 
State Medical and Pharmaceutical University, and Health Action International. The 
assessments covered the areas of: public procurement; main regulatory functions; 
availability, aff ordability, prices and price components of essential medicines; and 
an evaluation of the essential list of medicines, prescribing practices and pricing 
policies. The main recommendations of the report provide insights into ways of 
improving regulatory and procurement practices, along with the best methods to 
constrain the costs of medicines. 
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Objectives of this study
The purpose of this study is to provide the Ministry of Health with comprehensive 
evidence regarding the availability and aff ordability of good quality essential 
medicines in the Republic of Moldova. 
The study looks at:
 the possible barriers to the availability and aff ordability of essential medicines; 
 the level of prescription medicine prices in the Republic of Moldova in 
comparison with other countries;
 the prevailing prescribing practices with regards to generic and brand 
medicines;
 the extent to which the Moldovan authorities spend public funds on 
medicines which are most needed for the local population, in other words 
whether scarce resources are allocated optimally;
 the components of medicine prices and tries to identify where in the 
procurement and supply (PS) chain there may be opportunities for 
improvements with regard to distribution; and 
 whether through robust regulatory practices it is ensured that only medicines 
of the highest quality are available on the market.
The report is structured as follows:
 background to the organization and fi nancing of health care;
 methodology used to compile the material;
 results regarding access to medicines, PS and the rational use of medicines;
 discussion of the key points formulated above;
 conclusions and recommendations regarding issues identifi ed in the 
pharmaceutical system.
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Background
Population, health and epidemiology statistics: 
an overview 
In 2012, the total population of the Republic of Moldova was 3 559 500 (excluding the 
population on the left bank of the river Nistru and the town of Bender (Transnistria)). 
This was 5000 less than in 2011 and predominantly rural (urban to rural ratio: 0.72) (1). 
In 2010, gross domestic product (GDP) was €4383 million, corresponding to a GDP per 
capita of €1231 (at 2012 exchange rates) (2).
In 2010, life expectancy at birth was 65 years for men and 73 years for women (1). In the 
same year, the infant mortality rate for children aged under 1 year was 16 per 1000 live 
births (3). For children under the age of 5 years, the mortality rate was 19 per 1000 live 
births in 2010 (3). The maternal mortality ratio was 41 per 100 000 live births in 2010(3). 
Total health expenditure increased from €26.5 per capita in 1998 to €143.7 per capita in 
2010 (at current exchange rates) (Fig. 1). Between 1998 and 1999, there was a decrease 
in total health expenditure owing to the negative eff ect of the Russian crisis in the 
Republic of Moldova. Since 2000, however, total health expenditure has increased 
gradually from €25.5 per capita to €61 per capita in 2005 and €144 per capita in 2010. 
This remains far below the European average of €1585 per capita (2009 fi gures). 
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 Fig. 1. Total health expenditure per capita, 1998–2010
12 8 13 18 20 21 
25 33 
45 54 
70 71 78 
15 8 12 
15 20 19 
24 
28 
36 
44 
62 66 
66 
0
20
40
60
80
100
120
140
160
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Ex
pe
nd
itu
re
 p
er
 c
ap
ita
 (€
) 
Private health expenditure Government health expenditure
Source: WHO Global health expenditure database (4).
The proportion of total private spending has remained high, accounting for 54% of 
total health expenditure in 2010. More than half of out-of-pocket expenditure on 
health (70% in 2008, 73% in 2009 and 72% in 2010) was related to pharmaceuticals (4). 
The latest available data (2010) show that 83% of total private expenditure on health 
came from out-of-pocket sources, with the remainder coming from private health 
insurance. External sources of health care funding, such as international aid, play an 
important role, amounting to almost 10% of total health expenditure in 2010.1 
 In 2009, a WHO PS assessment mission to the Republic of Moldova estimated total 
pharmaceutical expenditure to be €126  million (unpublished data), compared with 
€69 million in 2005 (6). Pharmaceutical expenditure grew at an average rate of 8% per 
year between 2000 and 2005 (6) and 11% between 2005 and 2009.
The 2009 estimate of €126 million includes €11 million of locally produced and 
consumed pharmaceutical products (an additional €6 million of locally manufactured 
products is exported). The same assessement found that overall more than 91% 
(by value) of the medicines consumed in the country are imported (unpublished 
observations). Of total pharmaceutical spending, €25 million was publicly and 
€101 million was privately funded. 
1  In comparison to government and private expenditure as percentages of total health expenditure, 
which refer to financing agents, this indicator refers to the origin of the resources used to buy health 
services. Some of these external sources are channelled through the government budget, some through 
insurance agencies and some through the private sector or nongovernmental organizations. As such, 
these funds cannot simply be added to those reported in the earlier breakdowns (5).
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In terms of the disease burden, cardiovascular diseases are the main cause of mortality 
(66.3 deaths per 10  000 population), followed by cancer (16.1 deaths per 10  000 
population) and diseases of the digestive system (9.7 deaths per 10 000 population). 
Respiratory diseases (incidence rate (IR): 133.8 per 10 000 population) were the main 
cause of morbidity followed by trauma and poisoning (IR: 44.4) and infectious and 
parasitic diseases (IR: 30.1) (Table 1).
Table 1. Leading causes of mortality and morbidity, Republic of Moldova, 2009 
Disease
Death rate per 
year per 10 000 
populati on
Disease
Incidence per 
year per 10 000 
populati on
1 Cardiovascular diseases 66.3 Respiratory system 
  diseases
133.8
2 Cancer 16.1 Trauma and poisoning 44.4
3 Diseases of the digesti ve 
  system 
11.6 Infecti ous and parasiti c 
  diseases
30.1
4 Trauma and poisoning 9.7 Skin diseases 20.7
5 Respiratory system 
  diseases
6.5 Urogenital diseases 20.4
6 Infecti ous and parasiti c 
  diseases
2 Diseases of the 
  digesti ve system
19.7
7 Nervous system diseases 0.14 Cardiovascular diseases 16.8
8 Urogenital diseases 0.92 Osteoarti cular diseases 14.7
9 Complicati ons in the 
  perinatal period
0.56 Complicati ons during 
  pregnancy or birth
13.4
10 Congenital malformati ons 0.54 Eye diseases 9.4
 
Source: based on data from the National Centre of Health Management (7).
Policy frameworks relating to health
The national health policy was approved in 2007 (8) and an associated implementation 
plan was prepared in 2008. 
The offi  cial national medicines policy document was updated in 2002 and the 
associated implementation plan was updated in 2007. The implementation of 
pharmaceutical policy is regularly monitored and assessed by the Medicines Agency 
and the Ministry of Health. 
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Access to essential medicines/technologies, as part of the fulfi lment to the right 
to health, is recognized in the constitution or national legislation. There are offi  cial 
written guidelines on donations of medicines.
Health insurance
A system of national health insurance was introduced in 2004, fi nanced through the 
payroll tax (7% of salary, shared equally between the employer (3.5%) and the employee 
(3.5%)) or a fl at-rate lump sum for those who are self-employed (€167, or 2772 lei, in 
2011 (9)). The government makes contributions for those registered as unemployed. 
Vulnerable groups such as children aged under fi ve years, pregnant women and the 
elderly are exempt from premium contributions, which are fully subsidized by the 
government. 
In principle, health insurance is mandatory. In practice, however, coverage is not 
universal, mainly because a proportion of the self-employed and those employed 
in the large primary (mostly agricultural) sector often fail to pay contributions and, 
therefore, remain uninsured. Despite this, insurance coverage has grown steadily from 
66.8%2 of the total population in 2004 to 72% in 2009 and to 82% in 2010 (10), which 
corresponds to 18% of the population being uninsured in 2010. This is in line with 
fi ndings from a recent study in the country showing that 22% of the people interviewed 
(N=3760) had no health insurance (11). Factors associated with not being insured (as 
identifi ed through multivariate analysis) included: being self-employed in agriculture 
(odds ratio (OR): 27.31, 95% CI: 19.60–38.03 in comparison to employed people), being 
youth (age 24–34 years OR: 5.04, 95% CI: 3.25–7.81 in comparison to those aged 15–24 
years), being unemployed (OR: 4.72, 95% CI: 3.39–6.57 in comparison to employed 
people), being on a very low income (OR: 1.62, 95% CI: 1.13–2.34 in comparison to 
those with a very high income), and belonging to the male gender (OR: 2.07, 95% CI: 
1.65–2.6 in comparison to females) (11). 
The benefi t package covers most primary care services, emergency services and 
inpatient care. There can, however, be long waiting lists for some expensive high-
technology diagnostic instruments such as magnetic resonance imaging scans. The 
exact content of the benefi t package is redefi ned annually based on the available 
budget (11). In addition, all contracted service providers are required to off er some 
essential services to everyone regardless of their insurance status (11,12).
2  A diff erent source reports 75.7% health insurance coverage in 2004 (6).
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Methodology
This report is based on a secondary analysis of evidence collected during a series 
of missions conducted by the World Health Organization (WHO) Regional Offi  ce for 
Europe in collaboration with the Ministry of Health, the Medicines Agency, State 
University of Medicine and Pharmacy Nicolae Testemitanu of the Republic of Moldova 
and Health Action International. The following reports were included in this study:
 medicines prices, availability, and aff ordability and price components in the 
Republic of Moldova, 2012 (13); 
 PS assessment mission to the Republic of Moldova, 2011 (unpublished 
report);
 pharmaceutical country profi le, 2011 (7);
 medicines regulatory assessment report, 2011 (unpublished report). 
Evidence from these reports is complemented by information from peer-reviewed 
literature (11,14), the latest available health system profi le from the WHO Health 
Systems in Transition series (12), reports of international organizations (8,9,15), and 
grey literature (10) and insights obtained through interviews with a representative 
from academia in the country and the Deputy Director of the Medicines Agency. 
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Drug policy in the 
Republic of Moldova: 
evidence about performance
Registration and licensing of medicines
Registration of medicines and inspection of facilities
The Medicines Agency is facing a series of problems related to inspection and 
registration, which are largely the result of poor implementation of legislation, lack 
of funding and lack of suffi  cient human resource capacity to cope with the workload. 
First, although there is a bioequivalence requirement in the legislation, this is not 
being implemented so that the quality of generics remains questionable. The main 
reason for this is the lack of trained staff  and associated guidelines. The plan is for 
such guidelines to be developed and approved by the end of 2012, using European 
guidelines on bioequivalence as a model. 
Second, there are no legal provisions requiring the publication of a summary of 
product characteristics of the medicines registered. 
Third, temporary and conditional approval is not clearly defi ned in the legislation, 
although it is being implemented by the Ministry of Health.
Fourth, pressures from local and foreign manufacturers to register products quickly 
were reported during a 2011 WHO mission assessing procurement and systems for 
pharmaceuticals in the country. This causes a confl ict of interest in the Medicines 
Agency, which is tasked to ensure the quality and safety of medicines but, given its 
involvement in procurement (see section on procurement), also has an incentive to 
register medicines quickly, particularly low-cost generics so that they can be included 
in future tenders. 
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Fifth, there are other confl icts of interest within the Agency which need to be addressed, 
such as registration of inspectors  participating in trials to collect data for marketing 
authorization applications paid by manufacturers. 
Sixth, a registration timeline of 90 days applies to both originator and generic 
medicines, which is considered unrealistic. A motion was recently put forward in the 
parliament to extend the registration timeline to up to 210 days for all medicines, 
whether branded or generics.
Finally, there is limited capacity to inspect all new suppliers both in terms of human 
as well as fi nancial resources. The Medicines Agency does not receive any funding 
from the government and its only source of revenue is registration fees, which have 
remained unchanged over the past seven years (initially approved in 2003, revised 
in 2005). Quality control activities do not generate enough income to cover the 
associated costs. A 0.2% fee on the contract value of awarded tenders and modest 
revenues from advertisement authorizations are directed to fund activities at the 
Medicines Agency, although these are inadequate to compensate for the Agency’s 
work. The lack of funding goes some way towards explaining the Agency’s inability to 
fund local (let alone international) inspection activities and the negative impact this 
lack of resources has on staff  retention due to low salaries and motivation.
As an indication, the 2011 WHO PS assessment mission noted that over the past 5 
years only 3 of the top 20 producers in terms of the number of registered products 
were inspected (unpublished report). Inspection and quality assurance is, therefore, 
an important issue in the light of the high and growing import rates covering 
approximately one third of publicly procured products from countries which are not 
automatically considered as compliant with good manufacturing practice (GMP) (e.g. 
India and China) and, therefore, need to be visited for a GMP inspection before the 
product can be registered in the Republic of Moldova.3
The ability of the Medicines Agency to carry out inspections and to act quickly is 
weakened by the limited availability of GMP inspectors (one full-time and one-part 
time inspector) and by the need to have Ministry approval to inspect manufacturers. 
Further, there is no enforcement strategy defi ning applicable sanctions for non-
compliance with rules.
3  Either directly or indirectly through organizations with marketing authorizations in Germany and 
the United Kingdom but with actual manufacturing in Asia.
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Licensing of medicines and of facilities
There is no legal requirement for local manufacturers to comply with GMP although 
various draft regulations exist. As a consequence, of the 25 licensed manufacturers of 
pharmaceuticals in the Republic of Moldova, only 2 (which export to GMP-compliant 
countries) are GMP-certifi ed.
There seem to be an overlapping role and ill-defi ned responsibilities as between the 
Licensing Chamber and the Accreditation Offi  ce in inspecting pharmacies, wholesalers 
and manufacturers. 
There is no legal provision defi ning inspectors’ power and authority, which limits their 
availability to perform their duties. In addition, funding for inspections is not reliable.
The Medicines Agency is not involved in issuing licences for pharmacies, which means 
that new pharmacies open without prior inspection. 
National good pharmacy practice guidelines have been developed and sent for 
approval to the Ministry of Health. They are currently under revision.
Quality issues
There are concerns among medical staff  in government institutions about the 
quality and, as a result, about the effi  cacy of the available medicines. During a WHO 
mission in 2011, doctors reported problems of sub-standard medicines from China 
(ceftazidimum) and in locally manufactured medicines (methyl prednisolone and 
betamethasone). Further, three diff erent medicines with the same batch number 
were identifi ed in the pharmacy of one of the main hospitals in the capital. These 
three medicines were sourced from a local manufacturer (non-GMP- and non-GDP-
compliant) who was among the tender winners. 
One of the key issues aff ecting the quality of medicines in the country is the focus on quality 
control rather than quality assurance. The current system is considered unsustainable 
because it requires a very high number of tests which the national laboratory does not 
have the necessary capacity to run and, more importantly, it does not seem to be an 
eff ective tool for quality assurance. Further, the intensive testing approach very often 
causes additional delays in the supply chain.
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Monitoring and follow-up of blacklisted entities is haphazard. When a blacklist was 
in place, one of the companies on it bid again under another offi  cial entity and there 
was no legal basis for the Medicines Agency to reject this company in the tendering 
process.
A recall system for faulty products is available but does not work, as there are no 
standard operating procedures and no clear legislation assigning this responsibility to 
the Medicines Agency.
Finally (as indicated in an unpublished WHO report of medicines regulatory assessment 
in 2011), the cost and regulatory issues involved makes pharmacists reluctant to 
handle narcotics, which is causing problems with the availability of narcotic painkillers, 
particularly in rural areas.
Advertising and promotion
There are legal provisions for the control and promotion of pharmaceutical products, 
and the advertisement of prescription-only medicines and unregistered medicines 
is forbidden. Enforcement of the rules covering advertising is not, however, fully 
observed, a situation which is aggravated by the lack of defi nitions of promotion and 
advertising and requirements for advertisements.
There is no national code of conduct concerning the advertising and promotion of 
medicines by holders of marketing authorizations. In particular, the number of samples 
allowed, online advertisements, gifts to physicians, pharmacists and patients, training, 
trips and conferences sponsored by the industry are not regulated. 
Procurement
Public procurement is conducted by the Medicines Agency at national level. Following 
the national tendering process, local health care providers sign contracts with the 
tender winners in order to receive medicines. During visits to both state-owned 
and private wholesalers by the WHO PS assessment mission in 2011, full compliance 
with good distribution practice and the use of written formal standard operating 
procedures was not observed. In addition, owing to limited capacity and (possibly) 
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limited technical knowledge, the legal requirements for importation, distribution 
and the methods used for control are inadequate. This could seriously challenge the 
quality of medicines during transportation and storage.
Import and export
The price is taken into account in the evaluation of the application for importation 
and if it is perceived as being too high, permission to import is denied. This most likely 
aff ects the latest expensive therapies, including orphan drugs.
Pharmacovigilance
There are legal provisions requiring post-marketing surveillance, and a pharmacovigilance 
system is in place in the Medicines Agency. Some pharmacovigilance functions are 
performed, although not systematically, and there is no national pharmacovigilance 
centre linked to the Agency. The lack of reporting of adverse drug reactions is a serious 
problem. Doctors generally do not report adverse drug reactions due to the fear to be 
punished for reasons not related to reporting, for example, because they prescribed 
drugs that are not on the essential medicines list). It is generally part of the physicians’ 
culture to try to avoid every possible contact with regulators. 
Price monitoring
The government does not run an active national medicines price monitoring system 
for retail prices but the Medicines Agency monitors price indicators. Only the prices of 
the top-selling medicines are monitored rather than the prices of the most essential 
medicines. This is due to the absence of a system of offi  cial monitoring: distributors 
pay for monitoring and they are interested in collecting useful information for 
marketing purposes rather than generating new evidence for the benefi ts of public 
health policy. Further, there are no regulations requiring retail price information to be 
publicly accessible.
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Pricing and reimbursement of prescription drugs
Pricing of prescription medicines
Outpatient drugs
The prices of outpatient originator medicines are established through external 
reference pricing based on a basket of 10 countries.4 The average ex-factory price of 
the three lowest prices in the reference countries is estimated and proposed to the 
manufacturer. There is, however, little negotiation between the Medicines Agency 
and the manufacturer. On several occasions, manufacturers have refused the price 
proposed by the Medicines Agency and threatened not to market their products in 
the Republic of Moldova if the price proposed by the Agency was approved. This has 
caused delays which, in some cases, have led the Minister of Health to accept the 
prices proposed by the manufacturer(s). 
The lack of fl exibility in implementing the external reference pricing methodology has 
led in some cases to higher prices because one of the three lowest priced countries has 
a (much) higher price than the other two, thus pushing the average up.
For products which are not registered in other European Union (EU) countries, internal 
reference pricing is used to set the price. Prices are compared with comparable products 
(same level four or fi ve of the anatomic therapeutic chemical (ATC) classifi cation system) 
in the country.
Profi ts for local manufacturer prices should not exceed 15%. The MoH approves local 
manufacturer prices according to described internal reference price system and retail 
margins are capped to 15% of the ex-factory price.
The prices of registered medicines are reviewed annually. The prices of all (fi rst, second, 
etc.) generic medicines are capped at 75% of the originator brands’ prices.
Public and private pharmacies negotiate acquisition prices with distributors, 
although often distributors own pharmacies. This can lead to variations in the prices 
of prescription medicines across the country which, given that the national health 
insurance company reimburses up to a fi xed amount for each drug reimbursed, 
4  Belarus, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Lithuania, Romania, Serbia and Slovakia. 
On 1 April 2012, the criteria for choosing reference countries were changed to European countries with a 
population of up 25 million people. For practical reasons, the list of eligible countries was further reduced to 
those that were already included in the previous reference list and for which knowledge and experience was 
already available in extracting prices from the countries’ websites or in obtaining them from authorities. 
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may need to be matched by out-of-pocket payments. Pharmacists, distributors and 
manufacturers are able to negotiate discounts in transactions between them but 
the government does not have a clawback system allowing it to retain part of these 
discounts. Unoffi  cial sources suggest that discounts up to 99% of the cost of some of 
the most sold medicines exist in the system. 
Inpatient drugs
Tendering is used to procure inpatient medicines and medicines for national 
programmes, such as diabetes (insulin), analgesics (for palliative care), and drugs 
to treat HIV/AIDS, tuberculosis (TB) and other conditions. Tenders are issued by 
international non-proprietary name (INN) and both manufacturers and distributors 
are invited to participate. Contracts are awarded to the lowest price bidder and 
external reference prices are used as a guide in evaluating the prices off ered. Prices are 
expected not to exceed international reference prices but are not expected to be much 
lower than these either. The discounts obtained are usually comparatively higher for 
generics than for originator brands which, for in-patent products, is explained by their 
monopoly position. The availability of originator brands for patent-expired products 
is, however, limited. 
One of the main problems in obtaining low tender prices is the limited experience in 
the country in negotiating prices (staff  in the Medicines Agency tend to believe that 
prices proposed by manufacturers are the fi nal prices) and relatively weak bargaining 
position owing to the small market size. 
The 2011 WHO PS assessment mission noted that the national health insurance 
company reimburses the entire inpatient drug component (€13  million), which 
represents 10.3% of total expenditure on drugs. In addition the national health 
insurance company contributes €7 million towards outpatient drugs.
Distribution 
The number of pharmacists increased from 5.3 per 10 000 population in 2002 to 7.9 
in 2006 and 8.0 in 2009 (16). In June 2011, there were over 978 community-based 
pharmacies and subsidiaries, of which 350 were network pharmacies and the rest 
- individual pharmacies. This corresponds to more than 2.4 pharmacies per 10  000 
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population, representing a decrease since 2005 when there were 3.3 pharmacies per 
10 000 population (1111 in the whole country) (6). Pharmacies are not evenly distributed 
across the country: there are fewer than 1.6 pharmacies per 10 000 inhabitants in the 
rural regions of Causeni, Cimislia and Nisporeni and more than 4.5 pharmacies per 
10 000 inhabitants in the urban areas of Balti, Basarabeasca and Chisinau (6).
Distributors’ margins are regulated up to a maximum of 15% of the ex-factory price 
for wholesale mark-ups and up to 25% of the wholesale procurement price for retail 
mark-ups. There is no regressive or tiered margin structure, which means that these 
margins are fl at. 
A value-added tax of 8% is levied on all prescription-only drugs.
Reimbursement 
The Ministry of Health decides which medicines will be reimbursed. According to the 
regulations, reimbursement decisions should be made according to the following 
criteria: therapeutic effi  cacy/effi  ciency, economic effi  ciency, cost-effi  ciency, evaluation 
of the social perspective and price evaluation. In practice, there is no capacity or 
expertise to evaluate the cost-eff ectiveness of products and reimbursement decisions 
mainly rely on the burden of disease in the country as estimated through prevalence 
and incidence.
The level of reimbursement is established through data collection from 50 pharmacies 
across the country. Prices of all available formulations – originator brands, branded and 
unbranded generics – are collected. The median price of one unit (tablet, capsule or vial) 
is used to establish the reimbursement price (which is often only a percentage of it). 
All drugs dispensed in hospitals are reimbursed but only a small percentage of drugs 
prescribed in outpatient settings are reimbursed. For outpatient medicines, there is 
a four-tier reimbursement structure with reimbursement levels at 50%, 70%, 90% or 
100%, depending on the price of the drug. The 2011 PS assessment mission noted 
that the national health insurance company covers on average 50% of outpatient 
pharmaceutical expenditure on the essential medicines list, totalling €7 million per year 
in comparison to €13 million of inpatient pharmaceutical expenditure (unpublished 
observations). 
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Of the 393 INNs included in the essential medicines list (which was last updated in 
February 2011), 92  INNs are partially or fully reimbursed for diff erent population 
subgroups (all, children aged 0–5 years, children aged 0–18 years, pregnant women). 
Additional drugs such as insulin, analgesics for palliative care and drugs to treat HIV/
AIDS, TB and other conditions are available to all free of charge through national 
programmes.
As shown in Fig. 2, the largest group of reimbursed medicines is neurological drugs 
(27 INNs in total). Most of these drugs are available to all free (21 INNs), while a smaller 
number are available either at a reduced reimbursement rate (3 at 50% and 1 at 70%) 
or only for children aged 0–5 years (2 INNs). The second largest class of reimbursable 
drugs is cardiovascular drugs (18  INNs), although most of them (11 INNs) are only 
reimbursed at 50%, followed by alimentary tract and metabolism drugs such as 
nutrient supplements and diabetes medicines (14 INNs), and anti-infectives, including 
antibiotic drugs (12 INNs).
 Fig. 2. Number of INNs reimbursed by ATC group, reimbursement level and 
benefi ciaries, 2011
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All 90% All 100%
Children aged 0–5 years, 100% Pregnant women, 100%
Children aged 0–18 years, 100% 
Note. ATC-A: alimentary tract and metabolism; ATC-B: blood and blood forming organs; ATC-C: cardiovascular 
system; ATC-J: anti-infectives for systemic use; ATC-L: antineoplastic and immuno-modulating agents; 
ATCN: nervous system; ATC-P: antiparasitic products, insecticides and repellents; ATC-R: respiratory system; 
ATC-S: sensory organs; ATC-V: various; ATC-mix: diff erent ATC.
Source: Authors’ compliation based on the positive list and ATC/DDD Index 2012 (17).
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Because the positive list only contains 92 INNs out of a total of 393 INNs in the essential 
medicines list, and these 92 are often only partially reimbursed and not always for all 
patients, the list of reimbursable drugs is not enough to meet the basic health needs of 
the population. This potentially puts disadvantaged socioeconomic groups at serious 
risk of incurring high and potentially catastrophic out-of-pocket expenditure if they fall 
ill and need to buy their medicines themselves. This has even greater consequences 
for chronic diseases, as many drugs are reimbursed at 50% (11 INNs) and only 4 INNs 
at 70% and 3 INNs at 90%. 
Prescribing and generic substitution
Doctors prescribe medicines using brand names. In 2012, as part of the process of 
revising the order on prescribing and dispensing medicines, the Medicines Agency 
offi  cially proposed to introduce INN prescribing. However, after extensive discussions 
within the Ministry of Health and consultations with health professionals and the 
national health insurance company, the Ministry decided not to introduce INN 
prescribing. 
Another issue arises from doctors owning pharmacies in the clinics or hospitals 
where they practise (12). Combining clinical practice with drug dispensing can lead 
to confl icts of interest: doctors have an incentive to prescribe expensive drugs as well 
as potentially over-prescribe so as to increase their profi ts from dispensing (18), so 
supplier-induced demand could be signifi cant.
Generic substitution for prescription medicines is not allowed either for reimbursed 
or non-reimbursed medicines. For prescription medicines, if the doctor has prescribed 
a branded medicine the only way to obtain a generic equivalent is to get another 
prescription from the doctor using the drug’s INN. Given the limited availability 
of originator products in the country (less than 5% of total market share), this does 
not seem to be a major issue. It may, however, limit savings for the national health 
insurance company when a more expensive branded generic medicine is dispensed 
instead of a less expensive non-branded generic one. Considering that the market 
share of branded generics is 30–35% versus 60–65% for non-branded generics, this is 
likely to have some impact in terms of potential savings foregone.5 
5  The trade-off in the circumstances facing the Republic of Moldova is savings from cheaper 
(unbranded) generics versus concerns about the quality of the same medicines.
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Procurement and supply
There are three main ways in which pharmaceuticals can be procured or made 
available in the Republic of Moldova: centralized tendering, hospital tendering and 
direct purchase by pharmacies. The 2011 WHO PS assessment mission (unpublished 
report) noted that the pharmaceutical market relies heavily on imported medicines 
(91.4% of total value) and, to a lesser extent, on local production (8.6% of total value). 
In 2006, hospital procurement of medicines and devices was centralized and 
responsibilities were transferred to the Medicines Agency, which conducts annual 
tenders. This procurement method is also used for national programmes for the 
treatment of malaria, HIV/AIDS, TB, sexually transmitted diseases, noncommunicable 
diseases and the expanded programme on vaccines and immunization. It is not 
uncommon to have a very limited number of bidders or no bidder at all. If there is only 
one bidder, the tender is repeated a second time, after which a winner is nominated. 
In a few instances when only one bidder was available in both rounds, the price in the 
second tendering round was higher because the bidder knew to be in a  monopoly 
position and the Medicines Agency had to accept the second price off er. 
Table 2 presents data on the number of tenders, the budget available, the number 
of participants, and medicines tendered since the centralized tendering system was 
established in 2006. 
 Table 2. Centralized procurement of medicines, including national programmes, 2011 
Procurement 2006/2007 2007/2008 2008/2009 2009/2010 2010/2011
Organized tenders 46 41 46 37 57
Budget (million lei) 316.4 328.4 391.9 375.6 No data
Parti cipants (bidders) 
(average)
18 17 18 17 20
Medicines 1288 1216 1331 1551 1485
Source: WHO Regional Offi  ce for Europe (13).
The list of medicines to be tendered for is prepared by the Ministry of Health with the 
support of the main specialists and is based on the list of essential medicines. This list 
(using INN) is sent to all hospitals, which in turn provide information on the quantity 
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needed on an annual basis. Hospitals may procure medicines themselves if these 
medicines are not included in the tendering list, as long as they are able to provide a 
valid reason to the Medicines Agency. 
In cases of stock-out, hospitals are allowed to extend their existing contracts by up to 
30% of the original contracted volume. If this is not suffi  cient to cover the hospital’s 
needs, a new tender is announced.
Open national tenders are conducted annually with registered manufacturers and 
distributors. In practice, bidders are mainly distributors and a few local manufacturers. 
Tenders are awarded to the bidder off ering the lowest price. Each hospital receives 
supplies from the company awarded the tender (there is no central medical store).
Public and private pharmacies, on the other hand, acquire medicines through direct 
negotiation with wholesalers and/or local manufacturers. 
Delays are often caused by the need for the Public Procurement Agency to approve 
each step in the procurement process and to sign all the contracts, and by legal issues 
which may arise during the tendering process. In 2010, for example, a dispute over six 
products which went to court delayed the entire order for all the other 1300 products. 
In order to bid, tender participants must have a licence to practise pharmacy and a national 
GMP certifi cate (which is generally easy to obtain and does not ensure compliance with 
GMP), their medicines must be registered and have a remaining shelf life at delivery of 
not less than 60% for products with an expiry date of over two years and of not less than 
80% for products with an expiry date of under two years, including TB medicines. TB 
medicines and anti-diabetic products should follow GMP (according to the criteria of the 
WHO, the European Medicines Agency or the Food and Drugs Administration). If there is 
no GMP-compliant bidder, non-GMP-compliant bidders are accepted. 
There is very close involvement of the anti-corruption and competition authority at all 
stages in the tendering process. Their involvement in the activities of the Medicines 
Agency can be so close that it sometimes interferes with the Agency’s work, even in 
situations where there is no issue of corruption and competition. This is perceived as 
limiting the fl exibility of the PS chain management system for public procurement. 
Further, the fact that the mandate of this authority is not well-defi ned means that it 
can start investigations without offi  cial permission. This has a demotivating impact on 
the staff  involved in public procurement and is probably also partly responsible for the 
high staff  turn-over rate. 
19AVAILABILITY AND AFFORDABILITY OF MEDICINES AND ASSESSMENT OF QUALITY SYSTEMS 
FOR PRESCRIPTION OF MEDICINES IN THE REPUBLIC OF MOLDOVA
Another problem is the confl ict of interest between the regulatory function and the 
procurement function of the Medicines Agency. This leads to pressure to register 
products quickly, especially if they are less expensive than currently available 
alternatives, so that they can be included in the next tender. This obviously confl icts 
with the Agency’s responsibility for registration and quality control. Quality is further 
jeopardised by the lack of pre- and post-qualifi cation of suppliers. 
A World Bank report in 2010 (15) made several suggestions to strengthen the public 
procurement system, including: (i) aligning it with internationally accepted procedures 
for contract approval; (ii) making the complaint procedure independent of the Medicines 
Agency to avoid confl ict of interest; (iii) addressing work overload issues in the Medicines 
Agency, which approves more than 100 contracts a day with very limited capacity to 
carry out these functions; and (iv) developing the required secondary legislation referred 
to in the public procurement law but which is not yet ready. Finally, the roles and 
responsibilities of the Medicines Agency need to be revised (15). 
Many of the shortcomings in procurement stem from the fact that there are no written 
implementation procedures apart from public bidding. In addition to open tendering, 
the law allows for other procurement options such as limited tendering, framework 
agreement, negotiation, single-source procurement, invitation to quote and e-tenders. 
However apart from limited tender and single source procurement,  there is a lack 
of knowledge and experience among the people in charge of procurement and no 
regulatory implementation procedures exist for these other procurement methods 
(apart for limited tendering and single-source procurement). In such a scenario, written 
operational guidelines would help at least in part to address this capacity issue. 
Work is continuing in the Public Acquisition Agency to develop e-tender regulations. 
All pharmaceutical products imported into the Republic of Moldova have to be 
batch-tested. GMP-identifi ed manufacturers, in most cases concerning products from 
Europe, are exempt from testing. For these products a document check is suffi  cient, 
which takes two working days to produce. All other products have to be tested (no 
standard operating procedures provided for this). Owing to the immense constraints 
on capacity, delays of up to 20 working days are routine, and delays in testing are one 
of the most common reasons for drug shortages. In general, the supply of essential 
drugs to date is quite reliable and stock-outs of basic products are the exception rather 
than the norm. 
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Inequity in access to medicines
Pharmaceutical coverage as part of national health insurance is limited, causing high 
levels of out-of-pocket expenditure for patients (12,19). The situation is exacerbated by 
a weak safety net for lower socioeconomic groups, which are not exempt from out-of-
pocket payments, and it is even worse for elderly people who need to pay for the full 
cost of medicines not included in the limited drug benefi t basket. It is slightly better 
for noncommunicable diseases (such as diabetes) and some infectious diseases (such 
as HIV/AIDS and TB), as access to some of the medicines needed to treat these diseases 
is provided free of charge through national programmes funded by donors such as the 
Global Fund.
All medicines reimbursed in inpatient settings are fully reimbursed by the national 
health insurance company for insured people, potentially leading to patients accessing 
tertiary care to obtain free medicines. In 2011, the PS assessment mission noted that 
the national health insurance company paid €13 million for inpatient medicines 
out of a total €100 million paid for hospital services (unpublished observations). For 
reimbursed medicines dispensed in an outpatient setting (either public family doctor 
centres or private pharmacies), the national health insurance company pays a fi xed 
amount and the patient contributes the remainder, which is usually about 50% of the 
total drug price. 
Analysis of problems in access to medicines 
Much of the information in this section of the report is from a medicine price and 
availability survey conducted in 2011. The survey collected data on 50 medicines 
(all on the essential medicines list) in 50 public sector pharmacies (outpatients) and 
50 private pharmacies in the northern, central and southern regions of the country. 
Data were collected on originator brands (17 were registered out of the 50 sample 
medicines), the most sold generics (50), and the lowest- priced generics (50) in each 
facility, leading to a total sample of 117 drugs. The survey did not include the territories 
on the left side of the river Nistru and the town of Bender (Transnistria).
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Availability
The indicator used represents the overall mean availability of each of the samples of 
medicine in the facilities surveyed. 
Mean availability on the day of data collection was poor at 51.2% in public sector 
pharmacies (outpatients) and 58% in private retail pharmacies (Table 3). Of these 
medicines, the availability of originator brands was 15% and 23% in the public and 
private sectors, respectively; the availability most sold generics were 40% and 46%, 
respectively, and the availability of lowest- priced generics were 49% and 56%, 
respectively (Table 3).
 Table 3. Mean availability of medicines in the public and private sector, 2011
Product type
Mean availability (%)
Public sector Private sector
Originator brands (n=17) 15 23
Most sold generics (n=50) 40 46
Lowest- priced generics (n=50) 49 56
Any product type 51 58
Source: WHO Regional Offi  ce for Europe (13).
Availability in urban areas was higher in both public and private pharmacies for all 
product types. Originator brand medicines were available in 25% of urban and 5% of 
rural public pharmacies, and in 38% of urban and 8% of rural private pharmacies. The 
availability of the most sold generics was better but still low, at 58% of urban and 21% 
of rural public pharmacies, and in 62% of urban and 29% of rural private pharmacies. 
Overall, availability was highest for the lowest- priced generics, which were available 
in 68% of urban and 31% of rural public pharmacies, and in 72% of urban and 41% of 
rural private pharmacies ( Fig. 3).
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 Fig. 3. Pharmacies where medicines from the list were available, 2011
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Data on the availability of individual medicines shows that fi ve originator medicines 
are not available in public pharmacies and four are not available in private pharmacies. 
Only three of the generics were not available in any of the public pharmacies surveyed 
(clonazepam, clozapine, phenoxymethylpenicillin) and three were not available in 
any of the private sector pharmacies surveyed (clonazepam, clozapine, isosorbide 
dinitrate). None of the originator brands was available in more than 81% of both 
public and private pharmacies, while 10 generics were available in 81–99% of public 
pharmacies and 13 in private pharmacies, with 1 medicine (generic omeprazole) 
available in all the private pharmacies surveyed (13). 
Availability of all product types was higher in chain pharmacies in the private sector 
compared with individual pharmacies (Table 4). There was not a single pharmacy, 
whether public or private, where all 50 medicines surveyed were available on the day 
of the survey.
 Table 4. Availability of medicines in chain and individual pharmacies, 2011
Medicine Chain pharmacies (%) Individual pharmacies (%)
Originator brand 40 18
Most sold generic 65 40
Lowest - priced generic 76 50
Source: Adapted from (13).
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Overall, it appears that location rather than ownership is the determinant of availability, 
which is explained by the fact that most pharmacist-owned pharmacies are located 
in rural areas which are characterized by lower levels of availability in comparison to 
urban areas, as shown by the survey results. 
In summary, the availability of medicines was higher in urban than in rural areas and 
was higher for lowest-cost generics than for the most sold generics. The availability 
of originator products was particularly low, but this is not negative given that all the 
medicines surveyed are out of patent and generic alternatives exist on the market. The 
issue is the poor availability of these generic alternatives.
Prices
Two types of price comparison were made as part of the medicines access survey in 
order to help understand price levels in the country and their variation by type of 
medicine, geographical location and dispensing outlets.
The fi rst compared prices in the Republic of Moldova against international reference 
prices from the International drug price indicator guide 2010 (20). These reference prices 
are the medians of recent procurement prices off ered by for-profi t and not-for-profi t 
suppliers of generic products. These suppliers typically sell in bulk to governments 
or large nongovernmental organizations, and their procurement prices are therefore 
relatively low and represent effi  cient bulk procurement without the costs of shipping 
or insurance. The 2010 international reference prices were available for all the sample 
medicines. Prices are expressed as a median price ratio (MPR), that is, the unit price 
in the Republic of Moldova divided by the 2010 international reference unit price 
converted to local currency using the exchange rate on the fi rst day of data collection. 
When the MPR equals one, the local price equals the reference price; when the MPR 
equals two, the local price is twice as high as the reference price. 
The second compared prices in the Republic of Moldova against prices in six other 
European countries (Bulgaria, Germany, Hungary, Italy, Lithuania and Romania).
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Comparison of prices in the Republic of Moldova with international reference prices
MPRs in the public and private outpatient sectors
Table 5 shows that MPRs in the Republic of Moldova are much higher than international 
reference prices. The biggest diff erence was observed for originator brands in 
the private sector (8.77 times higher in the Republic of Moldova compared to the 
international reference prices). Overall, variations between minimum and maximum 
prices tended to increase with rising prices of medicines.
Although these MPRs show that median patient prices in the Republic of Moldova 
are four to nine times higher than international reference prices, the magnitude of 
this diff erence is infl ated because the 2010 MSH international reference prices are 
procurement prices based on bulk tendering prices and do not include distribution 
mark-ups and taxes (while patient prices in public and private facilities do). Even when 
these add-on costs are taken into account, however, it appears that median patient 
prices in the country are higher than international reference prices. 
A comparison of medicines found in both sectors showed that overall originator 
medicines were priced 6.3% higher in the private sector compared to the public sector 
(13). While the most sold generics were priced similarly in both sectors, the lowest- 
priced generics were priced 10.8% lower in the private sector than in the public sector 
(13). 
 Table 5. MPRs for pharmaceuticals in the public and private sectors, 2011 
MPR
Originator brand Most sold generic Lowest- priced generic
Public 
sector
Private 
sector
Public 
sector
Private 
sector
Public 
sector 
Private 
sector
Median MPR 7.64 8.77 6.72 6.78 5.22 4.65
25th percenti le MPR 2.76 3.44 3.23 3.30 2.90 3.03
75th percenti le MPR 18.74 29.02 9.36 9.76 7.28 7.12
Minimum MPR 0.45 0.46 0.64 0.67 0.64 0.64
Maximum MPR 117.26 125.58 82.33 84.00 43.07 44.30
No. of medicines 8 10 42 42 45 43
Source: WHO Regional Offi  ce for Europe (13).
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An analysis of price diff erences between the geographical regions showed that 
originator brands in the public sector were priced highest in the central region 
compared to the north and south, although few prices were found (Fig. 4). The most 
sold generics were also priced the highest in the central region. The lowest- priced 
generics were priced the highest in the north but were similar in price in the centre and 
south. Conversely, in the private sector, the median prices of originator brands were 
lowest in the central region, although the analysis was based on only a few medicines. 
The prices of the most sold and the lowest- priced generics in the private sector were 
similar across the three regions (Fig. 4).
 Fig. 4. MPRs for pharmaceuticals by geographical region, public and private 
sectors, 2011
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Source: WHO Regional Offi  ce for Europe (13).
 
In the public sector, overall prices to patients for originator brands were much higher 
in urban than rural areas, although there were only a few medicines in the dataset. For 
generics, there was little price variation between urban and rural areas (Fig. 5). In the 
private sector, prices in rural areas were higher than in urban areas for all three product 
types.
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Fig. 5. MPRs for pharmaceuticals by urban and rural areas, public and private 
sectors, 2011
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Source: WHO Global health expenditure database (4).
MPRs for centrally tendered inpatient medicines
Table 6 shows that median prices in the country are 1.68 to 2.39 times higher than 
international reference prices. In comparison to MPRs in the outpatient sector, these 
data show a more contained median price diff erence, which further supports the 
argument of the infl ated ratios when comparing international reference prices from 
bulk tendering with prices paid by patients at pharmacies in the country. In this case, 
the results in  Table  6 are based on a fair comparison, “like with like”, as only bulk 
tendering data were used to calculate the ratio. 
 Table 6. MPRs for centrally tendered medicines, 2011
MPRs Originator brands Most sold generics Lowest- priced 
generics
Median MPR 2.39 2.36 1.68
25th percenti le MPR 0.84 1.04
75th percenti le MPR 5.31 3.67
Minimum MPR 0.40 0.53 0.44
Maximum MPR 4.38 31.90 31.90
Number of medicines 2 17 45
Source: WHO Regional Offi  ce for Europe (13).
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Comparison of prices in the Republic of Moldova with prices in six European countries
This sub-section compares median retail in the Republic of Moldova with median 
prices in four other eastern European and two central European countries. 
Table 7 compares retail prices for originator brands in the private sector, but there are 
too few products in the comparison to draw reliable conclusions.
 Table 7. MPRs for originator pharmaceuticals in the private sector, 2011
Comparator 
countries
Median rati o 
comparator 
country
Minimum rati o Maximum rati o No. of medicines
Bulgaria 0.84 0.72 1.27 5
Germany 0.27 0.09 0.98 6
Hungary 1.17 1.09 1.63 4
Italy 0.65 0.08 2.60 5
Lithuania 1.01 0.62 1.34 8
Romania 1.13 0.87 4.88 6
Source: WHO Regional Offi  ce for Europe (13).
Based on prices reported by countries, median prices to patients in the Republic 
of Moldova for the lowest- priced generics were 11% lower than those in Bulgaria 
(MPR=0.89), 87% lower than in Germany (MPR=0.13) and 64% lower than in Italy (MPR 
0.36); similar to those in Hungary and Lithuania, but 13% higher than in Romania 
(MPR=1.13) (Table 8). 
 Table 8. MPRs for the lowest- priced generic pharmaceuticals in the private sector, 2011
Comparator 
countries
Median rati o 
comparator 
country
Minimum rati o Maximum rati o No. of medicines
Bulgaria 0.89 0.40 2.67 19
Germany 0.13 0.02 0.73 20
Hungary 0.96 0.15 4.40 18
Italy 0.36 0.07 1.40 15
Lithuania 0.95 0.07 2.00 20
Romania 1.13 0.5 4.00 19
Source: WHO Regional Offi  ce for Europe (13).
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These comparisons are, however, aff ected by two main limitations. The fi rst, for 
originator products, is the restricted number of drugs upon which the comparison 
is based (four to eight, depending on the comparator country). Given the wide 
price variations observed across the sample of 50 drugs (Table 5), it is likely that the 
small sample of drugs used to calculate the MPR in Table 7 is insuffi  cient to give a 
representative picture of the overall price diff erences. Second, comparisons are 
aff ected by the number of off -list price discount agreements in place in most of the 
comparator countries. In Germany discount agreements are widely used (21), as in 
Hungary, Italy and Lithuania, where a limited number of price-volume agreements 
are implemented (22–24). In countries where off -list price discounts, price-volume 
agreements, outcome guarantee agreements or claw-back agreements are in place, 
reported prices will mislead price comparison and lead to lower MPRs. 
In summary, median prices in the Republic of Moldova may not be as low as estimated 
by the data shown in Table 7 in the case of Germany and Italy, for example. If a number 
of price-volume agreements for the sample drugs are in place in Lithuania, the median 
prices in the Republic of Moldova could actually be higher, but this also depends on 
the representativeness of sample drugs. Indeed, minimum and maximum ratios in the 
Republic of Moldova in comparison to Lithuania indicate a rather wide variation (0.07–
2) in median price diff erences.
Comparison of ex-factory prices revealed that median prices in the Republic of 
Moldova are 14% higher than in the other six comparator countries and 44% higher 
than in Romania (12). These estimates are based on a total of 55 cases. 
Comparison of catalogue prices with tender prices for 
inpatient medicines
The ability of the tendering process to secure lower prices for medicines was 
investigated by comparing tendering prices for a sample of 234 medicines tendered 
for in 2011 with their catalogue prices. The results showed that the catalogue prices 
were higher than the tendered prices (median 7.51%) (Table 9). 
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Table 9. Median deviation of catalogue prices from tendering prices
Median price deviati on Deviati on (%)
Minimum deviati on -59.95
Maximum deviati on 686.47
Median deviati on 7.51
25 percenti le -11.44
75 percenti le 50.54
Source: based on publicly available tendering data.
Price components
Price component data were collected for six medicines (clarithromycin, diclofenac, 
salbutamol inhaler, fl uconazole, loratadine and paracetamol) in urban and rural areas 
in the public and private sectors (originator brands and generics). Starting at the point 
of sale in a pharmacy, price data were traced back through wholesalers/distributors 
and retailers (through invoices and interviews) to determine the components of the 
fi nal patients price. 
Almost no diff erence was observed in the wholesalers’ mark-up between sectors, product 
types, areas and source of manufacture (14.5–14.97%) (Table 10). Retail mark-ups were, 
however, higher than wholesalers’ mark-ups, except in the public sector in rural areas. 
Table 10. Price mark-ups by area, product type, source and sector 
(based on a sample of six medicines), 2011
Area Product type Source
Wholesale mark-up Retail mark-up Cumulati ve mark-up
Public
(%)
Private
(%)
Public
(%)
Private
(%)
Public 
(%)
Private 
(%)
Urban
Originator Imported 14.97 14.97 20.16–22.79 21.20–24.91 47.18–49.39 47.65–51.68
Generic Imported 14.50–14.97 14.97 22.77–24.98 20.71–22.95 49.36–51.78 47.12–49.59
Generic Local 14.97 14.97 22.61 24.43 48.59 50.55
Rural
Originator Imported 14.97 14.97 14.67–15 24.68–24.95 40.87–40.92 51.47–51.75
Generic Imported 14.97 14.87–14.97 14.93–14.98 18.08–25 40.59–41.53 44.19–51.78
Generic Local 14.97 14.97 14.73 24.13 40.08 50.55
Note. Cumulative mark-ups include 8% value-added tax. Mark-ups do not add up because they were calculated on the 
landed price or the price calculated after customs clearance and quality control procedures. As a result, they are lower than 
they would be if they were calculated on the wholesale or retail price.
Source: WHO Regional Offi  ce for Europe (13).
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Across the six medicines in the price component analysis, the manufacturers’ selling 
price was the greatest contribution to the fi nal price to patients (for originator brands 
and generics, public and private sector, imported and locally manufactured).
Fig. 6 shows the contribution of each stage to the fi nal price to patients (45.8 lei) 
for generic imported salbutamol inhaler in the private sector in urban areas. The 
manufacturers’ selling price is 68% of the fi nal price to patients. Very similar data were 
seen for the originator brands in the private sector and both product types in the 
public sector.
 Fig. 6. Retail price components for salbutamol inhaler, generic,
urban private sector, 2011
67,97% 
0,27% 
10,22% 
14,13% 
7,41% 
Ex-factory price
Cost included in the
procurement price
Warehouse mark-
up
Pharmacy mark-up
Value-added tax
Source: WHO Regional Offi  ce for Europe (13).
Fig. 7 shows the data for generic imported salbutamol inhaler in the private sector 
in rural areas. In this case, the wholesale and retail (pharmacy) mark-ups contribute 
slightly more to the price to the patient (45.6 lei) but the manufacturers’ selling price is 
the largest contributor at 66%.
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Fig. 7. Retail price components for salbutamol inhaler, generic,
rural private sector, 2011
65,93% 0,27% 
9,91% 
16,49% 
7,41% 
Ex-factory price
Cost included in the
procurement price
Warehouse mark-up
Pharmacy mark-up
Source: WHO Regional Offi  ce for Europe (13).
Price dynamics over time
Fig. 8 shows a decreasing trend in the share of low-priced medicines (≤ 10 lei), as well as an 
increasing trend in the share of expensive and very expensive medicines. Between 2010 and 
2011, however, there was a small increase in the share of low-priced medicines and a small 
decrease in the share of higher-priced medicines. Overall, the share of medicines priced 
10–50 lei has been relatively stable over the last three years, but these fi gures are based 
on data from only one wholesaler and are not representative of the entire country.
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Fig. 8. Evolution of medicine price groups, 2006–2011
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Source: WHO Regional Offi  ce for Europe (13).
In summary, the prices of originator products were lower in the public than in the 
private sector; the prices in the two sectors were similar for the most sold generics, 
while the prices for the lowest- priced generics were higher in the public sector than 
in the private sector. 
Aff ordability in the outpatient sector
The aff ordability of medicine was assessed as the number of days needed by a person 
on the minimum salary to buy medicines to treat a selection of common acute and 
chronic diseases, based on standard treatment regimens. At the time of the survey, 
the daily minimum wage was 20 lei. WHO and Health Action International consider 
that treatments are unaff ordable if a person on the minimum salary has to work more 
than one day to buy a course of treatment for an acute condition or 30 days’ supply of 
medicines used to treat chronic diseases.
Table 11 shows examples of some unaff ordable treatments in the public and private 
sectors for medicines to treat both acute and chronic conditions. As shown, those 
on the minimum wage would have to pay more than half their monthly income to 
purchase 30 days’ treatment for schizophrenia (clozapine), psychoses (risperidone), 
Parkinson’s disease (levodopa/carbidopa) and ulcerative colitis (sulfasalazine).
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 Table 11. Aff ordability of individual treatments in the public and private sectors, 2011
Treatment
Days’ wages
Public sector Private sector
Originator 
brand
Most sold 
generic
Lowest- 
priced 
generic
Originator 
brand
Most  
sold 
generic
Lowest- 
priced 
generic
Respiratory tract and other infec? ons
Amoxicillin 250 mg capsule x 21 0.9 0.9 0.9 0.9
Amoxicillin 125 mg/5 ml 
suspension, 60 ml 1.3
1.0 1.4 1.3
Ciprofl oxacin 500 mg capsule x 14 5.1 1.5 5.4 1.6
Cephalexin 250 mg capsule x 21 1.3 1.2 1.3 1.2
Clarithromycin 500 mg capsule x 7 6.6 15.5 6.8
Co-trimoxazole 480 mg tab x 14 1.1 0.5 1.2 0.4
Metrondazole 500 mg tablet x 21 2.1 4.8 1.8 2.1
Hypertension
Atenolol 50 mg tablet x 30 0.9 0.9 1.0 0.9
Amlodipine 5 mg tablet x 30 3.7 3.7 3.2 3.9 3.7
Captopril 25 mg x 30 1.6 0.6 1.7 0.6
Enalapril 5 mg tablet x 30  2.0 1.3 2.4 1.8
Enalapril 10 mg tablet x 30 2.3 1.7 2.4 1.8
Hydrochlorothiazide 25 mg 
tablets x 30
2.4 2.4
Lisinopril 10 mg tablet x 30 3.8 2.7 3.9 2.9
Verapamil 40 mg x 180 9.3 9.3 9.4 9.2
Hypercholesterolaemia
Simvastati n 20 mg tablet x 30 9.9 8.4 10.2 6.5
Asthma
Salbutamol inhaler 100 mcg x 
200 doses 2.4 2.2 2.2 2.6 2.3 2.3
Arthri? s/analgesia
Paracetamol 500 mg tablets x 120 3.5 1.3 1.3 3.6 1.3 1.3
Diclofenac 50 mg tablet x 60 17.9 1.3 1.4 19.1 1.4 1.5
Tramadol 50 mg x 120 8.1 8.7 9.2 9.3
Ulcer
Omeprazole 20 mg x 30 1.7 1.7 1.8 1.8
Raniti dine 150 mg x 60 2.9 2.5 3.0 2.2
Famoti dine 40 mg x 30 5.0 1.8 5.2 1.4
Depression/psychoses
Amitriptyline 25 mg x 30 2.5 2.5 2.7 2.6
Imipramine 25 mg tablet x 90 6.5 6.5 6.8 6.8
Fluoxeti ne 20 mg tablet x 30 5.0 5.0
Clozapine 100 mg tablet x 90 46.1 49.9
Risperidone 2 mg tablet x 90 31.2 32.1
Other
Sulfasalazine 500 mg tablet x 120 15.2 15.2 15.8 15.8
Levodopa+Cabidopa 250/25 mg x 90 29.3 29.3 31.1 31.1
Private sectorPublic sector
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Table 12 presents the diff erence in the aff ordability of medicines for 15 diseases with 40 
originator brands (10 originator brands were not found in any pharmacy), the most sold 
generics, and the lowest- priced generics in the public and private sectors. Given that 
prices vary across the country, the median average prices of these medicines were used. 
 Table 12. Aff ordability of medicines in the public and private sectors, 2011
Aﬀ ordability 
Number of medicines 
Price/minimum day wage <1 % (N=40)
More aﬀ ordable in the public sector 26 65.0
More aﬀ ordable in the private sector 8 20.0
Identi cal 6 15.0
Source: WHO Regional Offi  ce for Europe (13).
The data in Table 12 show that medicines sold in public pharmacies are more aff ordable 
in 65% of cases, while those sold in private sector pharmacies are more aff ordable in 
20% of cases. In 15% of cases, the level of aff ordability is identical for pharmacies in 
both sectors. Most of the medicines included in the survey were associated with some 
level of reimbursement: 13 were reimbursed at 50% for all, another 13 at 100% for all, 1 
at 90% for all, 8 at 70% for all, 5 at 100% for children aged 0–5 years and 1 at 100% for 
pregnant women. Only nine medicines were not reimbursed for anyone at any level. 
Based on the data on the number of days’ wages needed to buy one month of treatment, 
there could be aff ordability problems for lower socioeconomic groups, especially for 
uninsured people, although given the limited drug benefi t basket insured people are 
also likely to face access issues. This is further supported by evidence of the persistent 
catastrophic levels of health expenditure faced by both insured and uninsured 
households (aff ecting 5.8% of insured and 2.9% of uninsured households in 2010) (9). 
Expenditure on essential medicines
The 2011 tendering procurement list (for inpatient medicines only) contained a 
total of 1032 medicines (dosage- and pharmaceutical form-specifi c) of which 422 
(40.89%) were essential medicines, representing 43.14% of total spending on inpatient 
medicines (Table 13).
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 Table 13. Procurement volume for medicines on the lists of essential 
and non-essential medicines, 2011 
Volume and expenditure
Essenti al medicines 
list formulati ons 
procured
Non-essenti al 
medicines list 
formulati ons 
procured
Total number 
of formulati ons 
procured
Volume
Number of formulati ons 422 610 1032
Percentage 40.9% 59.1% 100%
Expenditure
Procurement volume (lei) 113 460 837 149 538 306 262 999 143
Percentage 43.1% 56.9% 100%
Source: based on the results of the two largest tenders (Nos.1317/11 of 26 August 2011 and1817/11 of 14 
November 2011).
Rational use of medicines
In theory, physicians should follow prescribing guidelines and prescribe drugs from 
the essential medicines list. In practice, they prescribe what they prefer without 
taking rational prescribing principles into account. One of the key issues is the lack of 
supervision of prescribing. In addition, there is a threat of supplier-induced demand by 
doctors who own pharmacies. This situation is further exacerbated by weak control of 
the promotion of medicines to physicians.
Another issue is the practice of pharmacists in charge of dispensing medicines in public 
pharmacies in primary health care units sometimes to dispense without prescriptions.
A greater eff ort is needed to promote the rational use of medicines. For example, there 
is no national programme or committee involving the government, civil society and 
professional bodies to monitor and promote the rational use of medicines (7). Further, 
evidence from a recent study of prescribing practices in the country which examined 
prescriptions in 2011 identifi ed 7.8% cases of overprescribing (26).
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Questions about the 
performance of drug policy 
Barriers to availability and aff ordability of medicines
Current situation. The overall availability of medicines in the Republic of Moldova is 
limited in both the public and private outpatient sectors (mean availability 51.2% and 
58%, respectively). Availability was particularly poor for originator products; it was better, 
although still limited, for the most sold and the lowest - priced generics. In rural areas it was 
poorer than in urban areas. This is partly explained by physical barriers to the distribution 
of medicines and the lack of economic incentive to open pharmacies in rural areas. 
Aff ordability varied between and within drug treatment groups. For respiratory tract 
and other infections, two drugs out of seven surveyed cost less than one day’s minimum 
wages in the public or private sectors. For hypertension, only two out of eight cost less 
than one day’s minimum wages in the public or private sectors, and one drug cost up 
to nine working days (verapamil). The highest prices were observed for two drugs for 
depression, clozapine and risperidone (only available as originator brands), which cost 
46.1 and 31.2 days’ minimum wages each. Given that not every individual is covered by 
health insurance, coupled with the limited coverage of medicines as part of the benefi t 
package, high prices pose a severe threat to patients’ access to treatment. 
Recommendations. It is not clear whether the selection of sample drugs itself was 
one of the main reasons for low drug availability. These drugs were selected from the 
Health Action International core list of drugs and essential drugs in the Republic of 
Moldova. If physicians do not follow rational prescribing principles and prescribe non-
essential drugs, which in turn will be procured by pharmacies in preference to essential 
drugs, the low availability might refer to essential drugs. To assess whether this is true, 
a survey of the availability of prescribed drugs should be conducted. 
Availability in rural areas could be improved by relying on a few large private or public 
outlets (for instance, part of a chain of pharmacies owned by a distributor) and a local 
public distribution system to rural health posts. In this way, transport costs for the private 
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sector would be reduced and economies of scale generated through bulk purchasing by 
a few large rural outlets, which would then redistribute medicines to local health posts.
In order to assure aff ordability, health insurance coverage should be extended to the 
entire population and the scope of the basic benefi t package for drugs broadened to 
include the entire essential medicines list. Special reimbursement conditions (such as 
exemption from out-of-pocket payments) should apply to the most vulnerable groups 
such as children, the elderly, chronically ill and disabled people and pregnant women. 
Prices of medicines in comparison with other countries
Current situation. According to the offi  cial prices published by four eastern and two 
central European countries, the median prices in the Republic of Moldova for the 
lowest- priced generics were 11% lower than those in Bulgaria (MPR=0.89), 87% lower 
than in Germany (MPR=0.13) and 64% lower than in Italy (MPR 0.36); similar to those in 
Hungary and Lithuania, but 13% higher in Romania (MPR=1.13).
Recommendations. In a number of cases, the list prices in other countries do not 
represent the actual price paid because of the existence of agreements between 
payers and manufacturers. The country should consider engaging in some form of 
discount or price-volume agreements for medicines with a high expected impact on 
the budget. This would help to bring down the annual expenditure on medicines by 
granting reimbursement for excess spending. France, for example, has successfully 
implemented a rebates agreement and Germany likewise a discount agreement. 
Another option could be to create regional purchasing groups for a limited number 
of products (such as small orders) with, for example, Romania, to increase purchasing 
power. Given that the language requirements for packaging in the Republic of Moldova 
are Romanian and Russian, this could be feasible. 
Prescribing practices with regard to generic and 
brand medicines
Current situation. Despite a recent attempt to introduce INN in 2012, doctors still 
prescribe using brand names. Further, generic substitution by pharmacists is not 
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allowed. If a doctor prescribes a branded medicine, the only way for a person to obtain 
a genetic equivalent is to get another prescription from the doctor using the INN name. 
Recommendations. A regressive margin structure should be introduced for wholesalers 
and pharmacists as an incentive to get them to procure and dispense low-cost generics 
over high-cost branded medicines. A further incentive for pharmacists to dispense 
generics could be a reward system in the form of a fl at price premium and/or a small 
percentage reward on the price of each generic prescription dispensed. Examples of 
countries implementing such systems include Denmark, France and Switzerland.
For generic substitution at pharmacy level to work eff ectively, information systems 
should be updated so that even if the branded name is entered into the system, a list 
of all the available generic options appears. 
Medical doctors should be trained to prescribe by INN during their university studies, 
and labelling requirements should mandate a large-font INN print-out and small-font 
brand names. 
Spending of public funds on essential medicines
Current situation. Only 40. 9% of all inpatient medicines procured in 2011 were essential 
medicines, as against 51.1% non-essential medicines. 
Recommendations. The essential medicines list has recently been updated and 
adapted to the needs of the population in line with WHO recommendations. Since the 
proportion of essential medicines procured appears to be rather low, eff orts should be 
made to procure more of them so as to improve rational drug use. Such eff orts should 
go hand in hand with promotion of rational prescribing.
Price components and where in the procurement 
and supply chain the situation could be improved
Current situation. The average wholesale margin in the Republic of Moldova is 14.9%, 
higher than in most other European countries, ranging from 3% in Sweden to 23% in 
the Netherlands with the majority varying between 4-8% of the retail price (according 
to data from 27 countries belonging to the EU since January 2007) (27).
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The margin for pharmacies (20.9%) is in line with the European average, which ranges from 
12% of the retail price in Romania and 50% of the retail price in Luxembourg (according to 
data from 15 of the 27 countries belonging to the EU since January 2007) (27).
Recommendations. The wholesaler margin is high in comparison with the average in 
other EU countries and should be lowered. In addition, a regressive margin system should 
be introduced to give an incentive for generic substitution as well as bulk discounts from 
wholesalers. The number of bands in the regressive margins structure should be limited 
to three or four to simplify implementation, although this will depend on the number 
of available prescriptions and their value. Retrospective analysis of consumption data is 
needed. Given the wide availability of generic and the modest availability of innovative 
products, the distribution of the value of available products is likely to be skewed to the 
right in the Republic of Moldova. In such situation it might be preferable to have two to 
three bands where most medicines are concentrated, and a larger band for products 
with lower frequencies.Above all, the structure of the margins needs to make sense for 
pharmacists, as they must not be disincentivised to stay in the market.
Assurance by the regulatory system that only good 
quality medicines are on the market
Current situation. There are issues of resource constraints, in terms of both human and 
fi nancial resources, when it comes to inspection of new suppliers, particularly suppliers 
in the far east such as China and India. There is only one GMP inspector in the whole 
country and regulations do not include fees for inspections. Other issues include the 
lack of clear regulation, fees and the high number of applications from the Asian region. 
Recommendations. It could be helpful for the Republic of Moldova to collaborate 
with other countries (such as neighbouring countries like Romania) and share 
responsibilities and costs for overseas inspections. 
Since it is impossible for all manufacturers to be covered, registration of medicines 
should be limited to countries with stringent regulartory authority.6 
The system needs to move from the current focus on quality control to quality assurance. 
6  A stringent drug regulatory authority is a regulatory which is (a) a member of the International 
Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH), or (b) an ICH observer, or (c) a regulatory authority associated with an ICH member through a 
legally binding mutual recognition agreement.
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Limitations
This study is subject to several limitations, including a few cases of divergent evidence 
from diff erent data sources which have been documented in footnotes. Owing to time 
constraints, it was only possible to have a few exchanges via telephone and e-mail with 
representatives of the Medicines Agency and the academic world, which limited the 
ability of the study to make a more in-depth analysis of some of the issues identifi ed. 
Comparison of prices in the Republic of Moldova with list prices in other European 
countries is aff ected by the presence of discounts off  list prices (for example price 
volume agreements, rebate contracts, etc.) in most European countries. 
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Conclusions and 
recommendations
The activities of the Medicines Agency, which combine oversight, regulation and 
procurement, are creating confl icts of interest. 
Regulations are not keeping pace with actual operational requirements. In addition, 
there is a strong infl uence, in practice not limited to oversight, by the Public 
Procurement Agency (the agency is part of the Ministry of Finance) which is causing 
substantial delays and, in a number of cases, hampering access to the most essential 
drugs. The lack of adequate operational regulations is leading to a lack of opportunity 
to use mechanisms other than centralized procurement. 
The main issues uncovered during the four studies and recommendations for 
addressing them are listed below.
Availability
Issues
 The geographical distribution of pharmacists and pharmacies is uneven.
 The availability of medicines in both the public and private sectors is poor.
 Remote areas are particularly aff ected by the limited availability of medicines 
owing to infrastructural problems (such as the limited road network) and the 
lack of economic incentives for pharmacists or distributors’ networks to open 
pharmacies in these areas.
Recommendations
 An incentive system could be introduced to encourage young pharmacists to 
work in rural areas. Experience with graduate medical doctors has shown that 
compulsory rural service works. It could be complemented through salaries 
and/or other benefi ts such as accommodation allowances. Incentives such as 
higher retail margins should be off ered to pharmacy owners to promote more 
pharmacies in rural areas. 
 The reasons for the limited availability of medicines need to be better understood 
and addressed. This could be done through interviews with pharmacists and 
wholesalers to understand where the bottlenecks are.
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Prices
Issues
 Comparison of ex-factory outpatient prices in the Republic of Moldova with 
prices in six European comparator countries shows that the country is aff ected 
by high ex-factory prices. A similar issue was identifi ed for tendering prices, 
which were only slightly lower (median 7.51%) than catalogue prices. This seems 
to be due to the limited skills and experience in price negotiation, coupled with 
reduced bargaining power because of the small market. 
 Savings from wholesale or retail discounts only benefi t the supply chain as 
there is no clawback system to transfer part of these savings to the national 
health insurance company. 
Recommendations
 Training in price negotiation is needed for staff  involved in tendering and 
purchasing outpatient medicines.
 A clawback system should be introduced to recover part of the savings obtained 
by wholesalers and retailers, but designed so that distributors do not lose the 
incentive to negotiate over prices.
 A system to monitor prices should be introduced.
Aff ordability
Issues
 The majority of drugs remain unaff ordable owing to high prices, incomplete 
coverage and limited benefi ts for drugs under the social health insurance.
 The list of reimbursed drugs is very limited and there are weak protection 
mechanisms for the chronically ill and the elderly.
Recommendation
 Universal health coverage and the comprehensiveness of the basic benefi t 
package for drugs should be broadened and safety-nets introduced for 
vulnerable groups.
Registration
Issues
 Pressure from local and foreign manufacturers to register products quickly 
and a lack of resources to inspect suppliers are leading to several marketing 
authorizations being granted without ensuring compliance with GMP.
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 The bioequivalence of generic with originator medicines is not being assessed.
 The current system relies on quality control and involves a large number of 
quality tests. Apart from the limited ability of this system to ensure quality, it is 
also consuming a very considerale amount of resources.
 The Medicines Agency does not receive any funding from the government and 
its only revenue comes from modest sources, such as registration fees, which 
have not been revised in the past seven years, quality control activities which 
do not even generate enough revenue to cover the costs, a 0.2% fee on the 
contract value of awarded tenders although this is not adequate to pay for the 
Agency’s work, and a modest revenue from advertising authorizations. 
 The number of staff  in the Agency and their level of training are not commensurate 
with the workload and the level of expertise required by their posts.
 Temporary and conditional approval is not clearly defi ned in the legislation, 
although it is being implemented by the Ministry of Health.
 Responsibility for registration (Agency Director or Minister of Health) is unclear.
 The new law mandates 210 days to register a medicine, whether branded or 
generic (European requirements mandate for 210 days to register a banded 
medicine and 90 days to register a generic medicine).
Recommendations
 There is a need to move from the current system of quality control to a system 
of quality assurance based on manufacturers’ compliance with GMP. Such 
compliance needs to become a legal requirement. 
 In order to contain expenditure on quality assurance while still assuring quality, 
the registration of medicines should be limited to those registered in countries 
with stringent regulatory authorities. 
 The development of bioequivalence guidelines, which was started in 
2012, should be completed and inspectors trained in the assessment of 
bioequivalence.
 Risk assessment should replace analysis of every registration sample.
 Issues related to the high turnover rate in the Agency should be addressed; 
stable funding for human resources ensured and staff  remunerated according 
to their duties and the level of expertise required; staff  should be provided 
with clear job descriptions which refl ect their realistic duties on a day-to-day 
basis; and they should be trained and off ered opportunities for continuing 
development.
 Conditions for temporary and conditional approval in regulations should be 
defi ned. 
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 The person responsible for registration (the Agency’s Director or the Minister 
of Health) should be defi ned in the law. In the interests of saving resources, it 
would be advisable that this should be the Agency’s Director.
 The registration timeline should follow European requirements.
Licensing
Issues
 There is no requirement for manufacturers, wholesalers and distributors to 
comply with GMP and good distribution practice.
 National good pharmacy practice guidelines are still being revised and are not 
yet available or being implemented.
 There is no legal requirement for pharmacists to be registered.
 Sometimes doctors own pharmacies, creating a confl ict of interest which could 
lead to overprescribing issues. 
 There is an overlap of roles and ill-defi ned responsibilities between the 
Medicines Agency, the Licensing Chamber and the Accreditation Offi  ce in 
relation to the inspection of pharmacies, wholesalers and manufacturers.
 Inspectors often lack the required (and continuing) training in areas such as GMP, 
good clinical practice, good laboratory practice and good distribution practice. 
 Inspectors’ power and authority are not defi ned in the legislation.
 The Medicines Agency does not have the necessary resources to inspect with 
the frequency stated in the law.
 The Medicines Agency needs the Ministry’s approval to inspect manufacturers.
 There is no enforcement strategy defi ning sanctions applicable for non-
compliance with rules.
Recommendations
 The draft legislation requiring manufacturers to comply with GMP should be 
fi nalized and enforced.
 Legal provisions requiring wholesalers and distributors to comply with good 
distribution practice are needed. 
 GMP, good distribution practice and national good pharmacy practice 
guidelines need to be published by the government and implemented.
 Legal provisions are needed requiring pharmacists to be registered.
 Regulations are needed to prevent confl icts of interest for doctors who own 
pharmacies.
 The fi nal goal should be to delegate responsibility for inspection activities 
entirely to the Medicines Agency. While working towards this, the roles 
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and responsibilities of the Medicines Agency, the Licensing Chamber and 
the Accreditation Offi  ce need to be defi ned in order to avoid overlap. Good 
communication and collaboration between the three agencies is essential.
 Inspectors need to be provided with continuing training so as to carry out their 
duties in a complex and dynamic regulatory environment. They also need to be 
provided with the power and authority to carry out their services. The extent of 
these should be clearly described in the law.
 The Medicines Agency needs a stable income to work effi  ciently. Possible 
sources of revenue should be reviewed and the fee structure for its services 
revised.
 The Ministry of Health should delegate the authority for inspection and 
enforcement to the Medicines Agency.
 A plan with clear deadlines to achieve compliance with good manufacturing, 
clinical, laboratory and distribution practices should be developed.
Market control and quality
Issues
 The current system is based on quality control, carrying out a very large amount 
of sample testing with a dubious impact on quality.
 There is no functional recall system for faulty products.
 The system for handling narcotics is overly restrictive and expensive and 
aff ecting the availability of painkillers.
 There is anecdotal evidence about the quality of medicines but the extent of 
the problem is not known. 
Recommendations
 The focus on quality control should change to a system of quality assurance 
developed by the manufacturer and controlled by the Medicines Agency.
 The number of samples for testing should be based on risk-assessment 
estimates.
 Standard operating procedures for recalling drugs should be developed, and 
their effi  ciency should be tested and evaluated.
 While making every eff ort to ensure the appropriate use of narcotics and 
prevention of abuses, regulations need to be relaxed so that pharmacies will be 
more willing to store narcotic painkillers.
 National quality control laboratories should be encouraged to participate in 
international schemes such as the WHO external assessment of offi  cial quality 
control laboratories, the WHO prequalifi cation medicines programmes, the 
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European Centre for Disease Prevention and Control network of biological 
laboratories, and the Offi  cial Medicines Control Laboratories network of the 
European Directorate for the Quality of Medicines & Health Care.
 A baseline study to assess the extent of the problem with and key issues in 
assuring the quality of drugs would be useful, with the objective of moving 
towards a system of quality assurance and compliance with good manufacturing 
and good distribution practices. This would allow assessment of the impact of 
the measures implemented, such as the introduction of quality management 
and mandatory compliance with good manufacturing and good distribution 
practices.
 Generic substitution should remain the over-arching policy objective, although 
decision-makers need to be mindful about the quality issues in the supply of 
generic medicines. Quality concerns may render generic substitution ineff ective 
and need to be addressed vigorously through inspections, a programme of 
extensive testing, accreditation of the relevant laboratories, capacity-building in 
these laboratories (where needed), and rationalization of the generic medicines 
in the supply of drugs.
Advertising and promotion
Issues
 There is a lack of regulatory requirements in a number of areas such as the 
number of samples allowed, advertising on the internet, and gifts from the 
industry to physicians, pharmacists and patients.
 Enforcement of the rules for advertising is weak.
Recommendations
 Advertising requirements should be in line with EU regulations.
 Advertisements by doctors and physicians should be prohibited.
Procurement
Issues
 Confl icts of interest could arise in the Medicines Agency because of its 
responsibilities for both the regulation and procurement of medicines.
 Centralized procurement is subject to delays and lack of fl exibility.
 Although tender contracts include penalties for failure or delay in supplying the 
market, they are rarely applied in cases of failure. The main reasons for hospitals 
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not to sue manufacturers are the time involved and the urgent need to fi nd an 
alternative supplier. 
 It is not unusual to have only one bidder or no bidder at all for a centralized 
tender.
Recommendations
 Procurement should be independent of the Medicines Agency so as to avoid 
confl icts of interest with the Agency’s other regulatory functions, such as 
registration.
 Procurement should be outsourced and centralized procurement limited.
 Central procurement should be limited to around the 300 most commonly 
needed drugs, while the bulk of procurement should be decentralized to 
hospitals.
 The procedure for sueing manufacturers who break the conditions for supplying 
drugs set out in tender contracts should be made effi  cient. A simple and fast 
procedure would encourage hospitals to act legally against manufacturers who 
breach contracts and provide a deterrent for such behaviour to happen again.
 Tenders should be published in English as well as the local language and 
advertised internationally (ideally using EU channels).
 The coordinating and oversight roles of the Public Procurement Agency should 
not become a reason for delays in tendering times.
 For the country to become an attractive market for manufacturers, it is 
essential that regulatory capacity is strengthened by gradually bringing it into 
alignment with EU standards. This will raise the profi le of the regulatory agency 
and will encourage manufacturers to do business in the country. Alignment 
with EU regulations is a long process, so a priority list and timeline for reforms 
should be prepared in consultation with WHO and possible business partners 
(manufacturers who do not yet sell their drugs in the country but who might do 
so if the necessary reforms are implemented). GMP requirements should be one 
of the top priorities for the country to become an attractive market. 
 In the meantime, and while the necessary reforms begin to be implemented, the 
following options should be considered to ensure a reliable supply of essential 
medicines: (i) direct imports, (ii) parallel imports, (iii) requests for assistance only 
to be addressed by EU countries because this will ensure that quality medicines 
will be imported, and (iv) (as a last resort) manufacturers to be informed of plans 
to use compulsory licensing for the procurement of innovative medicines.
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Import and export
Issue
 If the price of a medicine is higher than the registration price, authorization to 
import is denied.
Recommendation
 Price should not play a role in evaluating import applications in order not to 
detrement availability of innovative medicines.
Distribution
Issue
 There is a very large number of wholesalers in the Republic of Moldova who 
do not generally specialize in a particular therapeutic area but procure most 
of the medicines sold in the country, even if this means making frequent and 
small orders. This creates an additional burden for the Medicines Agency in 
terms of quality control and duplication of testing for the same medicine from 
all wholesalers. 
Recommendations
 Revising the wholesalers’ mark-up can generate the necessary incentive to 
wholesalers to move toward a more effi  cient structure and presence in the 
country.
 The Medicines Agency should hold the licence to sell a particular medicine 
and should deal directly with the medicines procurement agency. Distributors 
should only distribute the medicines. 
Rational use
Issue
 There is scope for signifi cant improvement in the rational use of medicines.
Recommendation
 A national programme to monitor and promote the rational use of medicines 
should be established and the involvement of professional bodies and civil 
society in such activities fostered.
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Post-market pharmacovigilance
Issues
 Pharmacovigilance activities are weak and need strengthening.
 There is little reporting by physicians.
 It is unclear whether any analysis of the data collected is conducted.
Recommendations
 A national pharmacovigilance centre linked to the Medicines Agency should be 
established to ensure coordination of these activities.
 Reporting should be facilitated through the establishment of an online 
reporting system and barriers to low reporting should be addressed. This 
could be done by establishing a dialogue with physicians, removing penalties 
which, although not related to reporting, may apply in cases of reporting (such 
as sanctions against a physician for dispensing drugs not on the essential 
medicines list), training physicians in reporting and including all physicians in 
the obligation to report. 
 The Agency needs to analyse the data collected and react to the fi ndings.
 Pharmacovigilance legislation should be updated and made compliant with EU 
law.
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